Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 121 to 135 of 298 results for breast cancer

  1. Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433

    Awaiting development [GID-TA11489] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer TS ID 11769

    Awaiting development [GID-TA11088] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Efectiveness of 26 Gy in 5 fractions over 1 week regimen in people receiving nodal irradiation- What is the effectiveness of radiotherapy given in 26 Gy in 5 fractions over 1 week compared with 40 Gy in 15 fractions over 3 weeks in people with early or locally advanced invasive breast cancer who are also offered nodal irradiation?

    fractions over 3 weeks in people with early or locally advanced invasive breast cancer who are also offered nodal irradiation? Any...

    Research recommendation
    Published
    7 August 2023

  4. Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]

    Awaiting development [GID-TA11089] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Image-guided vacuum-assisted excision biopsy of benign breast lesions (IPG156)

    Evidence-based recommendations on image-guided vacuum-assisted excision biopsy for benign breast lesions. This involves inserting a needle with a suction device through a small opening in the breast to remove non-cancerous lumps.

    Interventional procedures guidance
    Published
    22 February 2006
    View recommendations

    Sections for IPG156

  6. What is the adherence to, and satisfaction with, different intervention formats (for example, individual, group, virtual, and face to face) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the impact of greater adherence on effectiveness for different groups, such as: women, men, trans people and non-binary people people from minority ethnic family backgrounds people with learning disabilities or cognitive impairment, or physical disabilities, or both neurodiverse people?

    virtual, and face to face) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the impact of...

    Research recommendation
    Published
    5 May 2023

  7. What is the adherence to, and satisfaction with, different intervention formats (for example, individual, group, virtual, and face to face) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the impact of greater adherence on effectiveness for different groups, such as: women, men, trans people and non-binary people people from minority ethnic family backgrounds people with learning disabilities or cognitive impairment, or physical disabilities, or both neurodiverse people?

    virtual, and face to face) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the impact of...

    Research recommendation
    Published
    7 August 2023

  8. Postnatal care (NG194)

    This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.

    NICE guideline
    Published
    20 April 2021
    View recommendations

    Sections for NG194

  9. Maintaining and updating our guideline portfolio

    guidelines into 'topic suites'. We've started with the following: breast cancer cardiometabolic disease prevention and treatment mental...

  10. What is the most effective and cost-effective way of delivering the intervention (for example, type of physiotherapy or exercise, mode of delivery, number of sessions) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the acceptability of the intervention for different groups, such as: women, men, trans people and non-binary people people from minority ethnic family backgrounds people with learning disabilities or cognitive impairment, or physical disabilities, or both neurodiverse people?

    delivery, number of sessions) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the...

    Research recommendation
    Published
    5 May 2023

  11. Care and support of people growing older with learning disabilities (NG96)

    This guideline covers care and support for adults with learning disabilities as they grow older. It covers identifying changing needs, planning for the future, and delivering services including health, social care and housing. It aims to support people to access the services they need as they get older.

    NICE guideline
    Published
    11 April 2018
    View recommendations

    Sections for NG96

  12. Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]

    Awaiting development [GID-TA10960] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Strategies to reduce arm and shoulder problems- What is the most effective and cost-effective way of delivering the intervention (for example, type of physiotherapy or exercise, mode of delivery, number of sessions) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the acceptability of the intervention for different groups, such as: women, men, trans people and non-binary people people from minority ethnic family backgrounds people with learning disabilities or cognitive impairment, or physical disabilities, or both neurodiverse people?

    delivery, number of sessions) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the...

    Research recommendation
    Published
    7 August 2023

  14. Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]

    In development [GID-TA11400] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)

    Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    25 July 2018
    View recommendations

    Sections for TA533